Xu Ding, Liu Qing, Wang Jingzeng, Yin Enzhi, Zhou Biaohuan, Li Xiao, Shi Yulong
Department of Orthopedic Surgery, Ningbo No.6 Hospital, Ningbo, People's Republic of China.
Department of Respiratory and Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China.
J Bone Joint Surg Am. 2025 Apr 25;107(12):e63. doi: 10.2106/JBJS.24.01322.
Rotator cuff tears (RCTs) commonly lead to muscle atrophy, fatty infiltration, and fibrosis, resulting in pain, weakness, and impaired shoulder mobility. These pathological changes are often irreversible and pose substantial treatment challenges. The aim of this study was to evaluate the therapeutic potential of muscle-derived mitochondria (Mito) in mitigating muscle degeneration and fibrosis following RCTs.
Sprague Dawley rats were assigned to 3 groups: sham surgery, RCTs treated with Mito, or RCTs treated with phosphate-buffered saline solution (PBS). Following RCTs, in vivo Mito or PBS treatments were administered to the supraspinatus muscles (SSPs) of the rats immediately and then biweekly for 12 weeks. Data were collected on muscle morphology, fibrosis, fatty infiltration, oxidative stress, mitochondrial function, macrophage phenotypes, and serum inflammatory cytokines. In vitro experiments included mitochondria tracking in bone marrow-derived macrophages (BMDMs), characterization of macrophage polarization, and inflammatory cytokine profiling.
Isolated mitochondria preserved their morphology and function. Mito treatment improved muscle wet weight (p < 0.0001) and fiber cross-sectional area (p < 0.0001) while reducing fibrosis (p < 0.0001) and fatty infiltration (p < 0.0001). It upregulated mitochondrial markers cytochrome c oxidase (COX IV) and translocase of outer mitochondrial membrane 20 (TOMM20) (p < 0.0001) and enhanced antioxidative activity, as shown by increased superoxide dismutase (SOD) activity (p < 0.0001), elevated glutathione peroxidase (GSH-PX) levels (p = 0.038), and decreased malondialdehyde (MDA) levels (p = 0.0002). Mitochondrial density and morphology were restored in SSPs after Mito treatment. Additionally, Mito treatment induced an anti-inflammatory macrophage phenotype and reduced pro-inflammatory cytokines in vivo and in vitro.
Mito treatment mitigated muscle degeneration, improved mitochondrial function, and fostered an anti-inflammatory environment through macrophage modulation, demonstrating its potential as a cell-free therapeutic strategy for RCT-related muscle pathologies.
Although this is a preclinical study, its approach offers a novel avenue for improving RCT treatment outcomes. However, further validation in large animal models is needed to address the translational applicability of these findings, given the inherent regenerative capacity of rodent muscles.
肩袖撕裂(RCTs)通常会导致肌肉萎缩、脂肪浸润和纤维化,从而引起疼痛、无力和肩部活动能力受损。这些病理变化往往是不可逆的,给治疗带来了巨大挑战。本研究的目的是评估肌肉源性线粒体(Mito)在减轻RCTs后肌肉退变和纤维化方面的治疗潜力。
将Sprague Dawley大鼠分为3组:假手术组、接受Mito治疗的RCTs组或接受磷酸盐缓冲盐水溶液(PBS)治疗的RCTs组。在进行RCTs后,立即对大鼠的冈上肌(SSP)进行体内Mito或PBS治疗,然后每两周进行一次,持续12周。收集有关肌肉形态、纤维化、脂肪浸润、氧化应激、线粒体功能、巨噬细胞表型和血清炎性细胞因子的数据。体外实验包括在骨髓来源的巨噬细胞(BMDM)中追踪线粒体、巨噬细胞极化的特征分析以及炎性细胞因子谱分析。
分离出的线粒体保留了其形态和功能。Mito治疗改善了肌肉湿重(p < 0.0001)和纤维横截面积(p < 0.0001),同时减少了纤维化(p < 0.0001)和脂肪浸润(p < 0.0001)。它上调了线粒体标志物细胞色素c氧化酶(COX IV)和线粒体外膜转位酶20(TOMM20)(p < 0.0001),并增强了抗氧化活性,表现为超氧化物歧化酶(SOD)活性增加(p < 0.0001)、谷胱甘肽过氧化物酶(GSH-PX)水平升高(p = 0.038)和丙二醛(MDA)水平降低(p = 0.0002)。Mito治疗后,SSP中的线粒体密度和形态得以恢复。此外,Mito治疗在体内和体外均诱导了抗炎性巨噬细胞表型并减少了促炎性细胞因子。
Mito治疗减轻了肌肉退变,改善了线粒体功能,并通过巨噬细胞调节营造了抗炎环境,证明了其作为一种针对RCT相关肌肉病变的无细胞治疗策略的潜力。
尽管这是一项临床前研究,但其方法为改善RCT治疗结果提供了一条新途径。然而,鉴于啮齿动物肌肉固有的再生能力,需要在大型动物模型中进行进一步验证,以解决这些发现的转化适用性问题。